BioMedPartners
BioMedPartners is one of the leading European venture capital firms.
Business Model:
Revenue: $12.6M
Employees: 2-10
Rankings
Industries / Tags:
Detailed BioMedPartners Information
Geographic Data
Address: Elisabethenstr. 23
City: Basel
State: basel-country
Zip: 4051
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$75M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2011 | VAXIMM | Venture Round | 8M |
| 2/2011 | Activaero | Series A | 0 |
| 11/2009 | Activaero | Series A | 15.8M |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 9/2008 | Lumavita | Series A | 16.2M |
| 5/2012 | Spinelab | Series C | 4.8M |
| 11/2010 | Delenex Therapeutics | Series A | 14M |
| 11/2004 | Symetis | Series A | 9.6M |
| 5/2011 | Delenex Therapeutics | Series A | 19.3M |
| 6/2021 | Alentis Therapeutics | Series B | 66.8M |
| 5/2016 | Aleva Neurotherapeutics | Series C | 18M |
| 9/2014 | Affimed | Series E | 0 |
| 12/2010 | SuppreMol | Series C | 20.4M |
| 8/2011 | Aleva Neurotherapeutics | Series A | 13.7M |
| 6/2020 | TOLREMO therapeutics | Series A | 5M |
| 5/2013 | SuppreMol | Series D | 12.3M |
| 12/2019 | ImmunOs Therapeutics | Series A | 0 |
| 4/2010 | Affimed | Series C | 0 |
| 4/2016 | Anergis | Series C | 5.2M |
| 6/2018 | Tricares | Series B | 25.7M |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 3/2011 | Anergis | Series A | 20M |
| 11/2003 | Thommen Medical | Series C | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 12/2014 | AYOXXA | Series B | 2.9M |
| 10/2009 | Evolva | Series B | 27.8M |
| 11/2018 | Precirix | Series A | 41.9M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 10/2006 | Santhera Pharmaceuticals | Series C | 0 |
| 11/2014 | Humedics | Series C | 7.8M |
| 9/2018 | TOLREMO therapeutics | Series A | 9.3M |
| 12/2007 | Vivendy Therapeutics | Series A | 15.4M |
| 12/2019 | Aleva Neurotherapeutics | Series E | 8.1M |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 10/2013 | Middle Peak Medical | Series A | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 2/2006 | EyeSense AG | Series A | 0 |
| 1/2018 | Miracor Medical | Series D | 0 |
| 10/2016 | Miracor Medical | Series C | 0 |
| 1/2015 | Miracor Medical | Series B | 5.3M |
| 12/2014 | Anergis | Series B | 14.9M |
| 10/2015 | Sequana Medical | Series C | 0 |
| 3/2014 | Inotrem | Series A | 25.1M |
| 11/2014 | Curetis | Series B | 0 |
| 4/2014 | Sequana Medical | Series C | 26.1M |
| 9/2005 | Bioheart | Venture Round | 0 |
| 8/2005 | Dolthera GmbH | Series B | 18M |
| 9/2022 | Tricares | Series C | 0 |
| 4/2007 | Affimed | Series B | 32M |
| 10/2012 | Affimed | Series D | 20.1M |
| 12/2009 | Curetis | Series A | 27.9M |
| 9/2005 | Spinal Cord Therapeutics GmbH | Series A | 15.5M |
| 8/2009 | Spinelab | Series B | 10.2M |
| 2/2014 | Anergis | Series A | 8.9M |
| 4/2007 | Spinelab | Series A | 3.3M |
| 8/2006 | ESBATech | Series B | 41M |
| 3/2011 | Sequana Medical | Series B | 25.5M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 10/2007 | idiag | Venture Round | 3.8M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 8/2008 | ESBATech | Series B | 22M |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
| 10/2014 | ImevaX | Series A | 0 |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 12.3M |
| 3/2004 | CareX SA | Series B | 32M |
| 9/2017 | Amal Therapeutics | Series B | 9.5M |
| 11/2018 | Amal Therapeutics | Series B | 32.6M |
| 5/2022 | Tubulis | Series B | 0 |
| 2/2020 | Azafaros | Series A | 27.5M |
| 3/2004 | 4-Antibody AG | Seed Round | 2.1M |
| 4/2019 | Alentis Therapeutics | Series A | 12.3M |
| 4/2012 | Aleva Neurotherapeutics | Series B | 4.4M |
| 7/2008 | SuppreMol | Series B | 25M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 3/2022 | Precirix | Series B | 0 |
| 11/2013 | Delenex Therapeutics | Series A | 8M |
| 6/2022 | ImmunOs Therapeutics | Series B | 0 |
| 5/2022 | Tubulis | Series B | 0 |
| 3/2022 | Precirix | Series B | 0 |
| 3/2022 | Scenic Biotech | Series A | 0 |
| 8/2021 | Cardior Pharmaceuticals | Series B | 0 |
| 7/2021 | Topas Therapeutics | Series B | 0 |
| 6/2021 | Alentis Therapeutics | Series B | 0 |
| 12/2020 | Noema Pharma | Series A | 0 |
| 10/2020 | Topas Therapeutics | Series B | 0 |
| 7/2020 | Tubulis | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
